Synthesis and biological activity of Δ-5,6-norcantharimides: importance of the 5,6-bridge

European Journal of Medicinal Chemistry

Volumn 45, Issue 5, 2010, Pages 1717-1723

  Thaqi, Ali ^a   Scott, Janet L ^a   Gilbert, Jayne ^b   Sakoff, Jennette A ^b   McCluskey, Adam ^c  

^a MONASH UNIVERSITY   (Australia)

^b Calvary Mater Hospital   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

5,6 Ethyl bridge; Anti cancer; Cantharidin; Norcantharidin; Protein phosphatase 1 2A

Indexed keywords

5 BENZYL 2 HEXYLTETRAHYDRO 2H,3AH PYRROLO[3,4 C]PYRROLE 1,3 DIONE; ACID ANHYDRIDE; DELTA 5,6 NORCANTHARIMIDE DERIVATIVE; ETHER; NORCANTHARIDIN; OCTYLAMINE; OCTYLTETRAHYDRO 5H FURO[3,4 C]PYRROLE 4,6 DIONE; OXYGEN; PHOSPHOPROTEIN PHOSPHATASE; TETRAHYDROFURANO[3,4 C]FURAN 1,3 DIONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; RING OPENING;

ANTINEOPLASTIC AGENTS; CANTHARIDIN; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE; STEREOISOMERISM;

EID: 77949434151     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.01.004     Document Type: Article

References (41)

1. McCluskey A., and Sakoff J.A. Small molecule inhibitors of serine/threonine protein phosphatases. Mini Rev. Med. Chem. 1 (2001) 43-45
2. McCluskey A., Sim A.T.R., and Sakoff J.A. Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J. Med. Chem. 45 (2002) 1151-1175
3. McCluskey A., and Sakoff J.A. Protein phosphatase inhibition: structure based design. Towards new therapeutic agents. Curr. Pharm. Des 10 (2004) 1139-1159
4. Wang G.-S. Medical uses of mylabris in ancient China and recent studies. J. Ethnopharmacol. 26 (1989) 147-162
5. 3H]cantharidin binding site in relation to cytotoxicity. J. Pharmacol Exp Ther 280 (1997) 1152-1158
6. Einbinder J.M., Parshley M.S., Walzer R.A., and Sanders S.L. The effect of cantharidin on epithelial cells in tissue culture. J. Invest. Dermatol 52 (1969) 291-303
7. Wu J.Z., Situ Z.Q., Chen J.Y., Liu B., and Wang W. Antitumor-activity of psoralen on mucoepidermoid carcinoma cell-line MEC-1. Chin. Med. J. 105 (1992) 1026-1028
8. Li J.L., Cai Y.C., Liu X.H., and Xian L.J. Norcantharidin inhibits DNA replication and induces apoptosis with the cleavage in initiation protein Cdc6 in HL-60 cells. Anti-Cancer Drugs 17 (2006) 307-314
9. Bonness K., Aragon I.V., Rutland B., Ofori-Acquah S., Dean N.M., and Honkanen R.E. Cantharidin-induced mitotic arrest is associated with the formation of aberrant mitotic spindles and lagging chromosomes resulting, in part, from the suppression of PP2A alpha. Mol. Can. Therap 5 (2006) 2727-2736
10. Shan H.B., Cai Y.C., Liu Y., Zeng W.N., Chen H.X., Fan B.T., Liu X.H., Xu Z.L., Wang B., and Xian L.J. Anti-Cancer Drugs 17 (2006) 905-911
11. Kok S.H.L., Chui C.H., Lam W.S., Chen J., Lau F.Y., Wong R.S.M., Cheng G.Y.M., Tang W.K., Cheng C.H., Tang J.C.O., and Chan A.S.C. Mechanistic insight into a novel synthetic cantharidin analogue in a leukaemia model. Int. J. Mol. Med 18 (2006) 375-379
12. Huan S.K.H., Lee H.H., Liu D.Z., Wu C.C., and Wang C.C. Toxicol 223 (2006) 136-143
13. Kok S.H.L., Chui C.H., Lam W.S., Chen J., Tang J.C.O., Lau F.Y., Cheng G.Y.M., Wong R.S.M., and Chan A.S.C. J. Mol. Med 17 (2006) 151-157
14. To K.K.W., Wang X.N., Yu C.W., Ho Y.P., and Au-Yeung S.C.F. Bioorg. Med. Chem. 12 (2004) 4565-4573
15. Lin L.H., Huang H.S., Lin C.C., Lee L.W., and Lin P.Y. Chem. Pharm. Bull. 52 (2004) 855-857
16. McCluskey A., Bowyer M.C., Collins E., Sim A.T.R., Sakoff J.A., and Baldwin M.L. Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity. Bioorg. Med. Chem. Lett. 10 (2000) 1687-1690
17. McCluskey A., Walkom C., Bowyer M.C., Ackland S.P., Gardiner E., and Sakoff J.A. Cantharimides: a new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A. Bioorg. Med. Chem. Lett. 11 (2001) 2941-2946
18. Sakoff J.A., Ackland S.P., Baldwin M.L., Keane M.A., and McCluskey A. Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues. Invest. New Drugs 20 (2002) 1-11
19. McCluskey A., Ackland S.P., Bowyer M.C., Baldwin M.L., Garner J., Walkom C.C., and Sakoff J.A. Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines. Bioorg. Chem. 31 (2003) 66-77
20. Hart M.E., Chamberlin A.R., Walkom C., Sakoff J.A., and McCluskey A. Modified norcantharidins: synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity. Bioorg. Med. Chem. Lett. 14 (2004) 1969-1973
21. Hill T.A., Stewart S.G., Gordon C.P., Ackland S.P., Gilbert J., Sauer B., Sakoff J.A., and McCluskey A. Norcantharidin analogues: synthesis, anticancer activity and protein phosphatase 1 and 2A inhibition. ChemMedChem. 3 (2008) 1878-1892
22. McCluskey A., Keane M.A., Mudgee L.-M., Sim A.T.R., Sakoff J.A., and Quinn R.J. Is ring opening important in the inhibition of protein phosphatase 2A?. Eur. J. Med. Chem. 35 (2000) 957-964
23. Tatlock J.H., Linton A., Hou X.J., Kissinger C.R., Pelletier L.A., Showalter R.E., Tempczyk A., and Villafranca J.E. Bioorg. Med. Chem. Lett. 7 (1997) 1007-1012
24. 1, and 2B. Bioorg. Med. Chem. Lett. 7 (1997) 1833-1836
25. Laidley C.W., Dauben W.G., Guo Z.R., Lam J.Y.L., and Casida J.E. Structure-based design of novel calcineurin (PP2B) inhibitors. Bioorg. Med. Chem. 7 (1999) 2937-2944
26. Hill T.A., Stewart S.G., Gilbert J., Ackland S.P., Sauer B., Sakoff J.A., and McCluskey A. Heterocyclic substituted cantharidin and norcantharidin analogues - synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity. Bioorg. Med. Chem. Lett. 17 (2007) 3392-3397
27. Jones J.H., and Wood M.E. l-Histidine benzyl ester. Synth. Commun. 16 (1986) 1515-1516
28. Weigl M., and Wunsch B. Synthesis of chiral non-racemic 3-(dioxopiperazin-2-yl)propionic acid derivatives. Tetrahedron 58 (2002) 1173-1183
29. Pei W., Pei J., Li S., and Ye X. Stereoselective synthesis of 2-aryltetrahydrofuran-3,4-dicarboxylate derivatives: efficient approach to tetrahydrofuran lignans. Synthesis 14 (2000) 2069-2077
30. P.J. Crowley, S.P. Heaney, K.R. Lawson, D. Youle. Fungicides PCT Int. Appl. WO9507022, 1995.
31. Devys M., Barbier M., and Parisot D. Synthesis of Nectriafurone, an isofuranonaphthoquinone isolated from the fungus Nectria haematococca. Heterocycles 31 (1990) 1485-1490
32. Brown G.B., Baker B.R., Bernstein S., and Safir S.R. Biotin. II. 3,4-Trans-diaminothiophane. J. Org. Chem. 12 (1947) 155-159
33. Block E., Laffite J.A., and Eswarakrishnan V. Synthesis and reactions of 3-mercaptocyclobutanol and derivatives. Preparation of a 2,4-dithiabicyclo[3.1.1]heptane. J. Org. Chem. 51 (1986) 3428-3435
34. A. Hosomi. Method for the preparation of polycyclic 1,3-thiazolidines. Eur. Patent EP 307001, 1989.
35. Tominaga Y., Takada S., and Kohra S. S-silylmethyl-substituted ketene dithioacetals as synthetic equivalent of a novel 1,3-dipolar reagent, alkylidenethiocarbonyl ylide; synthesis and [3+2] cycloaddition reactions. Tetrahedron Lett. 35 (1994) 3555-3558
36. Pawda A., and Dent W. Use of N-[(trimethylsilyl)methyl]amino ethers as capped azomethine ylide equivalents. J. Org. Chem. 52 (1987) 235-244
37. Terao Y., Aono M., Imai N., and Achiwa K. Thiocarbonyl ylides VI. New generation of thiocarbonyl ylides from organosilicon compounds containing sulfur and their 1, 3-cycloadditions. Chem. Pharm. Bull. 35 (1987) 1734-1740
38. Bertini I., Calderone V., Fragai M., Luchinat C., and Talluri E. Structural basis of serine/threonine phosphatase inhibition by the archetypal small molecules cantharidin and norcantharidin. J. Med. Chem. 52 (2009) 4838-4843
39. Hill T.A., Stewart S.G., Ackland S.P., Gilbert J., Sauer B., Sakoff J.A., and McCluskey A. Norcantharimides, synthesis and anticancer activity: synthesis of new norcantharidin analogues and their anticancer evaluation. Bioorg. Med. Chem. 15 (2007) 6126-6134
40. Gupta V., Ogawa A.K., Du X., Houk K.N., and Armstrong R.W. A model for binding of structurally diverse natural product inhibitors of protein phosphatases PP1 and PP2A. J. Med. Chem 40 (1997) 3199-3206
41. Goldberg Y. Protein phosphatase 2A: who shall regulate the regulator?. Biochem. Pharmacol 57 (1999) 321-328